Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/17/2017 10/18/2017 10/19/2017 10/20/2017 10/23/2017 Date
21.525(c) 21.8(c) 20.575(c) 18.765(c) 18.57 Last
1 001 446 817 833 1 386 710 3 414 276 1 729 835 Volume
-0.55% +1.28% -5.62% -8.80% -1.04% Change
More quotes
Financials (€)
Sales 2017 232 M
EBIT 2017 40,9 M
Net income 2017 26,8 M
Debt 2017 10,9 M
Yield 2017 -
Sales 2018 322 M
EBIT 2018 58,8 M
Net income 2018 39,7 M
Debt 2018 85,0 M
Yield 2018 -
P/E ratio 2017 104,25
P/E ratio 2018 72,17
EV / Sales2017 12,0x
EV / Sales2018 8,87x
Capitalization 2 768 M
More Financials
Company
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies.It operates through the EVT Execute and EVT Innovate segments.The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes... 
More about the company
Surperformance© ratings of Evotec AG
Trading Rating : Investor Rating :
More Ratings
Latest news on EVOTEC AG
10/19 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/12 EVOTEC : achieves first milestone in neurodegeneration alliance with Celgene
10/10 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/10 EVOTEC : Achieves first milestone in neurodegeneration alliance with celgene
10/02 EVOTEC : invests in Exscientia to advance AI-driven drug discovery
09/29 EVOTEC AG : Release according to Article 26a of the WpHG [the German Securities ..
09/28 EVOTEC : Invests in Exscientia to Advance AI-Driven Drug Discovery
09/28 EVOTEC : Invests in exscientia to advance ai-driven drug discovery
09/21 EVOTEC : and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto
09/18 EVOTEC AG : Notification and public disclosure of transactions by persons
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/20Evotec short pitch at Robin Hood conference; shares fall 4%
1
10/19Forge Therapeutics, Evotec launch platform to discover metalloenzyme inhibito.. 
10/19Forge Therapeutics, Evotec launch platform to discover metalloenzyme inhibito..
1
10/12Evotec AG $EVTCY Upgraded at Zacks Investment Research  
10/12Evotec AG $EVTCY Rating Lowered to Hold at Zacks Investment Research  
More tweets
Qtime:76
News from SeekingAlpha
10/20 Evotec short pitch at Robin Hood conference; shares fall 4%
09/28 Evotec invests in Exscientia to advance AI-driven drug discovery
08/10 Evotec's (EVOTF) CEO Werner Lanthaler on Q2 2017 Results - Earnings Call Tran..
08/10 Evotec AG 2017 Q2 - Results - Earnings Call Slides
08/10 Evotec AG reports Q2 results
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 13,2 €
Spread / Average Target -30%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG152.15%3 261
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC35.48%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522